Search Results - "Arbour, K.C."

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib by Schoenfeld, A.J., Arbour, K.C., Rizvi, H., Iqbal, A.N., Gadgeel, S.M., Girshman, J., Kris, M.G., Riely, G.J., Yu, H.A., Hellmann, M.D.

“…Concurrent programmed death-ligand-1 (PD-(L)1) plus osimertinib is associated with severe immune related adverse events (irAE) in epidermal growth factor…”
Get full text

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer by Derosa, L., Hellmann, M.D., Spaziano, M., Halpenny, D., Fidelle, M., Rizvi, H., Long, N., Plodkowski, A.J., Arbour, K.C., Chaft, J.E., Rouche, J.A., Zitvogel, L., Zalcman, G., Albiges, L., Escudier, B., Routy, B.

“…The composition of gut microbiota affects antitumor immune responses, preclinical and clinical outcome following immune checkpoint inhibitors (ICI) in cancer…”
Get full text

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression by Aguilar, E.J., Ricciuti, B., Gainor, J.F., Kehl, K.L., Kravets, S., Dahlberg, S., Nishino, M., Sholl, L.M., Adeni, A., Subegdjo, S., Khosrowjerdi, S., Peterson, R.M., Digumarthy, S., Liu, C., Sauter, J., Rizvi, H., Arbour, K.C., Carter, B.W., Heymach, J.V., Altan, M., Hellmann, M.D., Awad, M.M.

“…In non-small-cell lung cancers with programmed death-ligand 1 (PD-L1) expression on ≥50% of tumor cells, first-line treatment with the PD-1 inhibitor…”
Get full text

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers by Sabari, J.K., Leonardi, G.C., Shu, C.A., Umeton, R., Montecalvo, J., Ni, A., Chen, R., Dienstag, J., Mrad, C., Bergagnini, I., Lai, W.V., Offin, M., Arbour, K.C., Plodkowski, A.J., Halpenny, D.F., Paik, P.K., Li, B.T., Riely, G.J., Kris, M.G., Rudin, C.M., Sholl, L.M., Nishino, M., Hellmann, M.D., Rekhtman, N., Awad, M.M., Drilon, A.

“…MET exon 14 alterations are actionable oncogenic drivers. Durable responses to MET inhibitors are observed in patients with advanced MET exon 14-altered lung…”
Get full text

COVID-19 in patients with lung cancer by Luo, J., Rizvi, H., Preeshagul, I.R., Egger, J.V., Hoyos, D., Bandlamudi, C., McCarthy, C.G., Falcon, C.J., Schoenfeld, A.J., Arbour, K.C., Chaft, J.E., Daly, R.M., Drilon, A., Eng, J., Iqbal, A., Lai, W.V., Li, B.T., Lito, P., Namakydoust, A., Ng, K., Offin, M., Paik, P.K., Riely, G.J., Rudin, C.M., Yu, H.A., Zauderer, M.G., Donoghue, M.T.A., Łuksza, M., Greenbaum, B.D., Kris, M.G., Hellmann, M.D.

“…Patients with lung cancers may have disproportionately severe coronavirus disease 2019 (COVID-19) outcomes. Understanding the patient-specific and…”
Get full text

Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas by Schoenfeld, A.J., Rizvi, H., Bandlamudi, C., Sauter, J.L., Travis, W.D., Rekhtman, N., Plodkowski, A.J., Perez-Johnston, R., Sawan, P., Beras, A., Egger, J.V., Ladanyi, M., Arbour, K.C., Rudin, C.M., Riely, G.J., Taylor, B.S., Donoghue, M.T.A., Hellmann, M.D.

“…Programmed death-ligand 1 (PD-L1) expression is the only FDA-approved biomarker for immune checkpoint inhibitors (ICIs) in patients with lung adenocarcinoma,…”
Get full text

503LBA LBA Orals: Results from CA240-0007, a phase 1/2 multiple expansion cohort study of BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del) by Rodon, J., Jänne, P.A., Leventakos, K., George, B., Henry, J.T., Johnson, M.L., Papadopoulos, K.P., Batista, A.I., Spira, C.P., Zhao, Y., Zuniga, R., Shoukier, M., Ernani, V., Haddox, C.L., Wozniak, A., Mariotti, V., Mazzei-Abba, A., Shazer, R., Yang, W., Arbour, K.C.

Get full text

652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) by Arbour, K.C., Punekar, S., Garrido-Laguna, I., Hong, D.S., Wolpin, B., Pelster, M.S., Barve, M., Starodub, A., Sommerhalder, D., Chang, S., Zhang, Y., Salman, Z., Wang, X., Gustafson, C., Spira, A.I.

Get full text

Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer by Ricciuti, B., Alessi, J.V., Elkrief, A., Wang, X., Cortellini, A., Li, Y.Y., Vaz, V.R., Gupta, H., Pecci, F., Barrichello, A., Lamberti, G., Nguyen, T., Lindsay, J., Sharma, B., Felt, K., Rodig, S.J., Nishino, M., Sholl, L.M., Barbie, D.A., Negrao, M.V., Zhang, J., Cherniack, A.D., Heymach, J.V., Meyerson, M., Ambrogio, C., Jänne, P.A., Arbour, K.C., Pinato, D.J., Skoulidis, F., Schoenfeld, A.J., Awad, M.M., Luo, J.

“…Allele-specific KRAS inhibitors are an emerging class of cancer therapies. KRAS-mutant (KRASMUT) non-small-cell lung cancers (NSCLCs) exhibit heterogeneous…”
Get full text

229P Clinicopathologic and genomic features of patients with mucinous lung adenocarcinoma and response to systemic therapies by Di Federico, A., Hong, L., Elkrief, A., Thummalapalli, R., Ricciuti, B., Alessi, J., Gogia, P., Pecci, F., Gandhi, M., Ladanyi, M., Zhang, J., Gibbons, D., Heymach, J., Nishino, M., Sholl, L., Awad, M., Arbour, K.C., Schoenfeld, A., Vokes, N., Luo, J.

Get full text

Acquired Resistance to KRASG12C Inhibition in Cancer by Awad, Mark M, Liu, Shengwu, Rybkin, Igor I, Arbour, Kathryn C, Dilly, Julien, Zhu, Viola W, Johnson, Melissa L, Heist, Rebecca S, Patil, Tejas, Riely, Gregory J, Jacobson, Joseph O, Yang, Xiaoping, Persky, Nicole S, Root, David E, Lowder, Kristen E, Feng, Hanrong, Zhang, Shannon S, Haigis, Kevin M, Hung, Yin P, Sholl, Lynette M, Wolpin, Brian M, Wiese, Julie, Christiansen, Jason, Lee, Jessica, Schrock, Alexa B, Lim, Lee P, Garg, Kavita, Li, Mark, Engstrom, Lars D, Waters, Laura, Lawson, J. David, Olson, Peter, Lito, Piro, Ou, Sai-Hong I, Christensen, James G, Jänne, Pasi A, Aguirre, Andrew J

“…A study involving 38 patients who initially had a response to adagrasib or who had a long period of stable disease in response to the drug but then had…”
Get full text